| 000 | 01618 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513200907.0 | ||
| 264 | 0 | _c20000119 | |
| 008 | 200001s 0 0 eng d | ||
| 022 | _a0902-0063 | ||
| 024 | 7 |
_a10.1034/j.1399-0012.1999.130612.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAschan, J | |
| 245 | 0 | 0 |
_aImproved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up. _h[electronic resource] |
| 260 |
_bClinical transplantation _cDec 1999 |
||
| 300 |
_a512-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aBone Marrow Transplantation |
| 650 | 0 | 4 |
_aBusulfan _xtherapeutic use |
| 650 | 0 | 4 |
_aCyclophosphamide _xtherapeutic use |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xmortality |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aLeukemia _xmortality |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aCarlens, S | |
| 700 | 1 | _aHägglund, H | |
| 700 | 1 | _aKlaesson, S | |
| 700 | 1 | _aMattsson, J | |
| 700 | 1 | _aRemberger, M | |
| 773 | 0 |
_tClinical transplantation _gvol. 13 _gno. 6 _gp. 512-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1034/j.1399-0012.1999.130612.x _zAvailable from publisher's website |
| 999 |
_c10572960 _d10572960 |
||